Erez Israeli: So just to make sure, we do see, obviously, the certain portion of like, by the way, happened everywhere in the world will become generic generics. At the same time, the market is growing as well. We recognize that trends along back, and I discussed it in previous meetings. This is why our main efforts and our main effort is about actually true innovation, patent protected, et cetera. We believe that the brands, our brands decided to continue to focus on will stay for a while like I just said.
Madhav Marda: Thank you, sir.
Operator: Thank you. [Operator Instructions] The next question is from the line of Bino Pathiparampil from Elara Capital.
Bino Pathiparampil: Good evening. Just a question on a couple of products in the U.S. One, you had acquired the ANDA to generic Lumify from Slayback Pharma? What’s the status when do you expect an approval?
Erez Israeli: Sorry, can you repeat the product.
Bino Pathiparampil: Generic version of ANDA from generic version of Lumify which you acquired from Slayback Pharma?
Erez Israeli: Yes. So what is the question?
Bino Pathiparampil: What it the status. I believe it was already filed when you acquired it. When do you expect approval and launch?
Erez Israeli: So the best of my knowledge is approved product by now.
Bino Pathiparampil: Sorry, what is it?
Erez Israeli: It’s an approved product by now. You asked whether it will get approved, it’s approved.
Bino Pathiparampil: Okay. And any timelines for the launch?
Richa Periwal: We expect the launch to happen in this quarter only.
Bino Pathiparampil: This quarter, Okay. Second, I believe you are also working on the peptides. So any update on what – how do you see the liraglutide opportunity panning out over the next two, three years?
Erez Israeli: So yes, indeed, this is a very important segment for us. Long-term, we put a lot of efforts. We are still putting efforts on both the API as well as the finished goods globally. We are planning to do it in each one of the market. Specifically for the product, both Victoza and Saxenda, obviously, we have what we believe are the date for launch for each one of them, and we want to launch when we can.
Bino Pathiparampil: Is it like a couple of years away or four years away? What the rough idea of when you see the opportunity coming up?
Erez Israeli: Each one of these products, there is a date. I don’t – I cannot confirm a date.
Richa Periwal: At an appropriate time.
Erez Israeli: At this stage, we cannot. But whenever the market will be open, we are planning to be there.
Operator: Thank you. Ladies and gentlemen, that will be the last question for today. I would now like to hand the conference over to Ms. Richa Periwal for closing comments. Over to you, ma’am.
Richa Periwal: Thank you all for joining us for today’s evening call. In case of any further queries, please get in touch with the Investor Relations team. Thank you once again on behalf of Dr. Reddy’s Laboratories Limited. That concludes this conference. You may now disconnect your lines.
Operator: Thank you. On behalf of Dr. Reddy’s Laboratories Limited, that concludes this conference, ladies and gentlemen. We thank you all for joining us. You may now disconnect.
